Leerink analyst Marc Goodman initiated coverage of MapLight Therapeutics (MPLT) with an Outperform rating and $30 price target The firm is bullish on the muscarinic space and says MapLight’s lead asset ML-007C-MA has a potentially better clinical profile than Cobenfy. ML-007C-MA is in Phase 2 development for the treatment of Alzheimer’s disease psychosis, which is a large market with significant unmet need, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MPLT:
- Promising Investment in MapLight Therapeutics: Buy Rating Backed by Strategic Positioning and Strong Financials
- Buy Recommendation for MapLight Therapeutics: Promising Pipeline and Market Potential
- MapLight Therapeutics initiated with a Buy at Stifel
- MapLight Therapeutics initiated with a Buy at Jefferies
- MapLight Therapeutics initiated with an Overweight at Morgan Stanley